References
- Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;2008(6):480–487.
- Angastiniotis M, Vives Corrons J-L, Soteriades ES, et al. The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders. ScientificWorldJournal. 2013;2013:727905.
- Weiss M, Parisi Jun M, Sheth S. Clinical and economic burden of regularly transfused adult patients with β-thalassemia in the United States: a retrospective cohort study using payer claims. Am J Hematol. 2019;94(5):E129–E132.
- Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, et al. Economic burden of thalassemia major in Iran, 2015. J Res Health Sci. 2016;16(3):111–115.
- Farmakis D, Giakoumis A, Angastiniotis M, et al. The changing epidemiology of the ageing thalassaemia populations: a position statement of the Thalassaemia International Federation. Eur J Haematol. 2020;105(1):16–23.
- Koren A, Profeta L, Zalman L, et al. Prevention of β thalassemia in Northern Israel – a cost-benefit analysis. Mediterr J Hematol Infect Dis. 2014;6(1):e2014012.
- Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion. 2016;56(5):1038–1045.
- Ahmadnezhad E, Sepehrvand N, Jahani FF, et al. Evaluation and cost analysis of national health policy of thalassaemia screening in west-azerbaijan province of iran. Int J Prev Med. 2012;3(10):687–692.
- Yang Y, Li D-Z, He P. A program on noninvasive prenatal diagnosis of α-thalassemia in Mainland China: a cost-benefit analysis. Hemoglobin. 2016;40(4):247–249.
- McQuilten ZK, Higgins AM, Burns K, et al. The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. Transfusion. 2019;59(11):3386–3395.
- Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6(3):177–179.
- Cappellini MD, Viprakasit V, Taher AT, et al. BELIEVE Investigators. A Phase 3 Trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020;382(13):1219–1231.
- Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479–1493.
- Coquerelle S, Ghardallou M, Rais S, et al. Innovative curative treatment of beta thalassemia: cost-efficacy analysis of gene therapy versus allogenic hematopoietic stem-cell transplantation. Hum Gene Ther. 2019;30(6):753–761.